Compare · NVCN vs ZOM
NVCN vs ZOM
Side-by-side comparison of Neovasc Inc. (NVCN) and Zomedica Corp. (ZOM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVCN and ZOM operate in Pharmaceuticals and Biotechnology (Health Care), so they compete in similar markets.
- ZOM is the larger of the two at $284.2M, about 10.2x NVCN ($27.8M).
- ZOM has more recent analyst coverage (1 ratings vs 0 for NVCN).
- Company
- Neovasc Inc.
- Zomedica Corp.
- Price
- $30.03+1.35%
- $0.10-3.15%
- Market cap
- $27.8M
- $284.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Pharmaceuticals and Biotechnology
- Pharmaceuticals and Biotechnology
- Exchange
- NASDAQ
- AMEX
- IPO
- 2017
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 1
Neovasc Inc.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, Canada, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Zomedica Corp.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Latest NVCN
- Volato Announces Changes to Board Composition
- SEC Form EFFECT filed by Neovasc Inc.
- SEC Form 15F-12B filed by Neovasc Inc.
- SEC Form 6-K filed by Neovasc Inc.
- SEC Form 6-K filed by Neovasc Inc.
- SEC Form RW filed by Neovasc Inc.
- SEC Form F-10POS filed by Neovasc Inc.
- SEC Form POS AM filed by Neovasc Inc.
- SEC Form S-8 POS filed by Neovasc Inc.
- SEC Form 25-NSE filed by Neovasc Inc.
Latest ZOM
- Diality Appoints Peter Donato as Chief Financial Officer
- Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv
- Zomedica Expands TRUFORMA(R) Diagnostic Menu with Launch of Equine Progesterone Assay
- Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review
- Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential
- Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth
- Zomedica Announces Launch of the Assisi Loop Lounge(R), Scientifically Backed tPEMF(TM) Therapy for Pets
- Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union
- Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October "Fourth Friday at Four" Webinar
- Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay